Sign In
test

Jared Keller

Kynam Capital Management, Lp

Assets Managed
$1.621B
Holdings
37
Last Quarter
2026 - Q1
Filed Date
11d ago
Growth Rate
3.56%(2Q avg: 10.06%)
Sustained Growth
3 quarters

Portfolio positions

This chart displays the top 10 holdings in Kynam Capital Management, Lp's 2026 - Q1 portfolio, based on their 13F SEC filing, out of a total of 37 positions.

Assets under management

The assets under management (AUM) of Kynam Capital Management, Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 3 quarters. As of the latest 13F SEC filing for 2026 - Q1, they manage 1.621B in assets, with a quarterly growth rate of 3.56% and a 2-quarter average growth rate of 10.06%. The portfolio is managed by Jared Keller, and others.

Portfolio holdings

InvestmentPortfolio %Reported Value
SNDX
Syndax Pharmaceuticals Inc
Recent Activity
11.61%
$188.07M
8.051M shares@ $23.36 avg price
CLDX
Celldex Therapeutics Inc
Recent Activity
Decreased -1.72%
11.43%
$185.263M
5.841M shares@ $31.72 avg price
PCVX
Vaxcyte Inc
Recent Activity
10.48%
$169.817M
2.922M shares@ $58.12 avg price
COGT
Cogent Biosciences Inc
Recent Activity
Decreased -34.51%
9.59%
$155.397M
4.037M shares@ $38.49 avg price
VERA
Vera Therapeutics Inc
Recent Activity
Decreased -1.01%
8.44%
$136.711M
3.398M shares@ $40.24 avg price
BEAM
Beam Therapeutics Inc
Recent Activity
Increased 9.04%
5.42%
$87.746M
3.682M shares@ $23.84 avg price
TVTX
Travere Therapeutics Inc
Recent Activity
Increased 368.05%
4.45%
$72.015M
2.424M shares@ $29.72 avg price
CTMX
Cytomx Therapeutics Inc
Recent Activity
Increased 67.45%
4.36%
$70.562M
15.013M shares@ $4.7 avg price
BCRX
Biocryst Pharmaceuticals Inc
Recent Activity
Decreased -39.35%
3.34%
$54.081M
5.681M shares@ $9.52 avg price
VRDN
Viridian Therapeutics Inc
Recent Activity
Increased 59.24%
2.83%
$45.803M
2.342M shares@ $19.56 avg price

1-10 of 37